0.445
-0.015
(-3.26%)
Real-time:
10:17am BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 0.44 - 0.45 |
| 52 week | 0.34 - 0.82 |
| Open | 0.46 |
| Vol. | 526,905.00 |
| Mkt cap | 7.61M* |
| P/E | - |
| Div/yield | - |
| EPS | 0.00* |
| Shares | 1,711.18M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | -1831.82% | -1000.58% |
| Operating margin | -2058.18% | -1086.09% |
| EBITD margin | - | -1048.80% |
| Return on average assets | -42.94% | -43.88% |
| Return on average equity | -45.11% | -45.75% |
| Employees | 9 | - |
| Carbon Disclosure Rating | - | - |
Address
24 Greville Street
LONDON, ENG EC1N 8SS
United Kingdom - Map
+44-20-30084416 (Phone)
+44-20-30084415 (Fax)
LONDON, ENG EC1N 8SS
United Kingdom - Map
+44-20-30084416 (Phone)
+44-20-30084415 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
ValiRx Plc is an investment holding Company. The Company is engaged in developing technologies and products in oncology therapeutics and diagnostics. The Company operates in two segments: drug development and the sale of self-test drug kits. The Company is also engaged in developing a groundbreaking class of therapeutics based on the GeneICE platform and hypergenomics technology. The Company�s subsidiaries include ValiRx Bioinnovation Limited, which is the holding company, ValiPharma Limited, which is engaged in the therapeutic research and development; ValiMedix Limited, which is a medical diagnostics company and ValiRx Finland OY, which is engaged in therapeutic research and development. On August 18, 2011, the Company acquired ValiRx Finland OY. On January 5, 2012, the Company acquired Pharmatest Services Oy.
Officers and directors
| Nicholas Thorniley | Chairman of the Board of Director | |
| Satu Vainikka | Chief Executive Officer, Director | |
| Gerald Desler | Chief Financial Officer, Director | |
| George Morris | Chief Operating Officer, Director | |
| Kevin Alexander | Secretary, Non-Executive Director | |
| Oliver de Giorgio-Miller | Non-Executive Independent Director |